Journal article
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer
The oncologist (Dayton, Ohio), v 24(8), pp 1095-1102
Aug 2019
PMID: 30975923
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
This article reports the results of a group of patients in a phase II study that assessed the combination of seribantumab and erlotinib in non‐small cell lung cancer patients whose tumors were EGFR wild‐type.
Metrics
Details
- Title
- Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer
- Creators
- Lecia V. Sequist - Massachusetts General HospitalJhanelle Elaine Gray - Moffitt Cancer CenterWael A. Harb - Horizon Oncology CenterAriel Lopez-Chavez - Oregon Health & Science UniversityRobert C. Doebele - University of Colorado DenverManuel R. Modiano - Arizona Research CenterDavid Michael Jackman - Dana-Farber Cancer InstituteMaria Quintos Baggstrom - Washington University in St. LouisAkin Atmaca - Institute of Clinical Cancer ResearchEnriqueta Felip - Vall d'Hebron Hospital UniversitariMariano Provencio - Hospital Universitario Puerta de Hierro MajadahondaManuel Cobo - Instituto de Investigación Biomédica de MálagaBambang Adiwijaya - Merrimack Pharmaceuticals (United States)Geoffrey Kuesters - Merrimack Pharmaceuticals (United States)Walid S. Kamoun - Merrimack Pharmaceuticals (United States)Karen Andreas - Merrimack Pharmaceuticals (United States)J. Marc Pipas - Merrimack Pharmaceuticals (United States)Sergio Santillana - Merrimack Pharmaceuticals (United States)Byoung Chul Cho - Yonsei UniversityKeunchil Park - Samsung Medical CenterFrances A. Shepherd - Princess Margaret Cancer Centre
- Publication Details
- The oncologist (Dayton, Ohio), v 24(8), pp 1095-1102
- Publisher
- John Wiley & Sons, Inc
- Number of pages
- 8
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:000481426100035
- Scopus ID
- 2-s2.0-85064534030
- Other Identifier
- 991022059861304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Oncology